Back to Search

AUGMENT-102: A Phase 1, Open-label, Dose-escalation Study to Evaluate Safety, Tolerability and Preliminary Anti-Leukemic Activity of SNDX-5613 in Combination With Chemotherapy in Patients With Relapsed/Refractory Leukemias Harboring Alterations in KMT2A/MLL, Nucleophosmin 1 (NPM1), and Nucleoporin 98 (NUP98) Genes

  • Protocol Number: 202206042
  • Principal Investigator: Dipersio, John
  • Cancer Types: Leukemia, Myeloma, and Hematologic

For more information on this trial, contact us here:


Brief Summary

Protocol Interventions